235 related articles for article (PubMed ID: 32807831)
1. ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target.
Liu D; Gunther K; Enriquez LA; Daniels B; O'Mara TA; Tang K; Spurdle AB; Ford CE
Sci Rep; 2020 Aug; 10(1):13906. PubMed ID: 32807831
[TBL] [Abstract][Full Text] [Related]
2. ROR1 and ROR2 play distinct and opposing roles in endometrial cancer.
Henry CE; Llamosas E; Daniels B; Coopes A; Tang K; Ford CE
Gynecol Oncol; 2018 Mar; 148(3):576-584. PubMed ID: 29395309
[TBL] [Abstract][Full Text] [Related]
3. Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.
Henry C; Llamosas E; Knipprath-Meszaros A; Schoetzau A; Obermann E; Fuenfschilling M; Caduff R; Fink D; Hacker N; Ward R; Heinzelmann-Schwarz V; Ford C
Oncotarget; 2015 Nov; 6(37):40310-26. PubMed ID: 26515598
[TBL] [Abstract][Full Text] [Related]
4. The Role of ROR1 in Chemoresistance and EMT in Endometrial Cancer Cells.
Lee KJ; Kim NH; Kim HS; Kim Y; Lee JJ; Kim JH; Cho HY; Jeong SY; Park ST
Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241228
[No Abstract] [Full Text] [Related]
5. miR-379-5p inhibits proliferation and invasion of the endometrial cancer cells by inhibiting expression of ROR1.
Liang M; Chen H; Min J
Acta Biochim Pol; 2021 Jun; 68(4):659-665. PubMed ID: 34115460
[TBL] [Abstract][Full Text] [Related]
6. MIR-379-5p Expression in Endometrial Cancer and Its Correlation with ROR1 Expression.
Mosaad H; Abdelrahman AE; Abdullatif A; Lashin ME; Ramadan MSH; El-Azony A; Hussien MHS
Asian Pac J Cancer Prev; 2023 Jan; 24(1):239-248. PubMed ID: 36708573
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.
Zhang S; Cui B; Lai H; Liu G; Ghia EM; Widhopf GF; Zhang Z; Wu CC; Chen L; Wu R; Schwab R; Carson DA; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17266-71. PubMed ID: 25411317
[TBL] [Abstract][Full Text] [Related]
8. miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer.
Tao J; Zhi X; Zhang X; Fu M; Huang H; Fan Y; Guan W; Zou C
J Exp Clin Cancer Res; 2015 Nov; 34():139. PubMed ID: 26576539
[TBL] [Abstract][Full Text] [Related]
9. ROR1 and ROR2 expression in pancreatic cancer.
Liu D; Sharbeen G; Phillips P; ; Ford CE
BMC Cancer; 2021 Nov; 21(1):1199. PubMed ID: 34763666
[TBL] [Abstract][Full Text] [Related]
10. Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
Parker BA; Shatsky RA; Schwab RB; Wallace AM; ; Wolf DM; Hirst GL; Brown-Swigart L; Esserman LJ; van 't Veer LJ; Ghia EM; Yau C; Kipps TJ
Breast Cancer Res Treat; 2023 Jun; 199(2):281-291. PubMed ID: 37029329
[TBL] [Abstract][Full Text] [Related]
11. Meta-Analysis of Survival Effects of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1).
Jeong SY; Lee KJ; Cha J; Park SY; Kim HS; Kim JH; Lee JJ; Kim N; Park ST
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557069
[TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1.
Islam SS; Uddin M; Noman ASM; Akter H; Dity NJ; Basiruzzman M; Uddin F; Ahsan J; Annoor S; Alaiya AA; Al-Alwan M; Yeger H; Farhat WA
EBioMedicine; 2019 May; 43():211-224. PubMed ID: 31085100
[TBL] [Abstract][Full Text] [Related]
13. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.
Yu J; Chen L; Cui B; Widhopf GF; Shen Z; Wu R; Zhang L; Zhang S; Briggs SP; Kipps TJ
J Clin Invest; 2016 Feb; 126(2):585-98. PubMed ID: 26690702
[TBL] [Abstract][Full Text] [Related]
14. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.
Cui B; Zhang S; Chen L; Yu J; Widhopf GF; Fecteau JF; Rassenti LZ; Kipps TJ
Cancer Res; 2013 Jun; 73(12):3649-60. PubMed ID: 23771907
[TBL] [Abstract][Full Text] [Related]
15. New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactome.
Raivola J; Dini A; Salokas K; Karvonen H; Niininen W; Piki E; Varjosalo M; Ungureanu D
Cell Mol Life Sci; 2022 May; 79(5):276. PubMed ID: 35504983
[TBL] [Abstract][Full Text] [Related]
16. Twist promotes tumor metastasis in basal-like breast cancer by transcriptionally upregulating ROR1.
Cao J; Wang X; Dai T; Wu Y; Zhang M; Cao R; Zhang R; Wang G; Jiang R; Zhou BP; Shi J; Kang T
Theranostics; 2018; 8(10):2739-2751. PubMed ID: 29774072
[No Abstract] [Full Text] [Related]
17. Targeting ROR1 identifies new treatment strategies in hematological cancers.
Karvonen H; Niininen W; Murumägi A; Ungureanu D
Biochem Soc Trans; 2017 Apr; 45(2):457-464. PubMed ID: 28408486
[TBL] [Abstract][Full Text] [Related]
18. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies.
Daneshmanesh AH; Porwit A; Hojjat-Farsangi M; Jeddi-Tehrani M; Tamm KP; Grandér D; Lehmann S; Norin S; Shokri F; Rabbani H; Mellstedt H; Österborg A
Leuk Lymphoma; 2013 Apr; 54(4):843-50. PubMed ID: 22988987
[TBL] [Abstract][Full Text] [Related]
19. ROR1 expression as a biomarker for predicting prognosis in patients with colorectal cancer.
Zhou JK; Zheng YZ; Liu XS; Gou Q; Ma R; Guo CL; Croce CM; Liu L; Peng Y
Oncotarget; 2017 May; 8(20):32864-32872. PubMed ID: 28427197
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the prognostic significance of receptor tyrosine kinase-like orphan receptor 1 (ROR1) in lung carcinoma and its relation to lymphangiogenesis and epithelial mesenchymal transition.
Heabah NAE; Darwish SA; Eid AM
Pathol Res Pract; 2023 Aug; 248():154703. PubMed ID: 37481855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
